Spruce Street Capital LP

The most arresting move inside that group is Alto Neuroscience (ANRO). The position barely registered in December at under $4 million — a rounding error in a 27-name book. By March, ANRO sat at $29 million as the sixth-largest holding, a 500-percent increase in three months. That is not a rebalance on a thesis already proven right; it is a rapid escalation that signals the manager saw something in the data or the pipeline that changed the position's expected value sharply. Relmada Therapeutics tells a similar but smaller story — roughly $20 million at year-end grew to $43 million, making it the largest name in the book as of March 31. Kiniksa Pharmaceuticals went from $18 million to $37 million. Dianthus Therapeutics roughly doubled from $12 million to $31 million. These are not opportunistic size-ups of mildly favorable names; they read like concentrated bets on specific catalysts.

The eight new names are each small enough to fit comfortably inside a spreading thesis rather than COMMAND one, but they are not trivial either. Enliviven, Alkeremes, and Perspective Therapeutics each arrived at $10 million or more, giving the fund eleven names at that size — a meaningful cluster for a book that was running closer to six $10M-plus names at the end of last year. Lynx Acquisition Corp, the SPAC vehicle, is the only name in the new cohort that carries the speculative-event risk; the rest are clinical-stage or commercial-stage specialty pharma plays with specific pipelines rather than general biotech beta.